The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy

Roy van der Meel, Marc H. Symons, Robert Kudernatsch, Robbert J. Kok, Raymond M. Schiffelers, Gert Storm, William M. Gallagher, Annette T. Byrne (Corresponding author)

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

67 Citaten (Scopus)

Samenvatting

It has become increasingly apparent that current antiangiogenic therapy elicits modest effects in clinical settings. In addition, it remains challenging to treat cancer metastasis through antiangiogenic regimes. Rho GTPases are essential for vascular endothelial growth factor (VEGF)-mediated angiogenesis and are involved in tumour cell invasion. This review discusses novel therapeutic strategies that interfere with Rho GTPase signalling and further explores this network as a target for anticancer therapy through interference with tumour angiogenesis and invasion. Recent findings describe the development of innovative Rho GTPase inhibitors. Positive clinical effects of Rho GTPase targeting in combination with conventional anticancer therapy is of increasing interest.

Originele taal-2Engels
Pagina's (van-tot)219-228
Aantal pagina's10
TijdschriftDrug Discovery Today
Volume16
Nummer van het tijdschrift5-6
DOI's
StatusGepubliceerd - mrt. 2011
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit